MaxCyte, Inc. (LON:MXCT) Insider Stan Erck Sells 47,689 Shares

MaxCyte, Inc. (LON:MXCT) insider Stan Erck sold 47,689 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of GBX 388 ($5.19), for a total transaction of £185,033.32 ($247,503.10).

MaxCyte Stock Performance

Shares of LON MXCT opened at GBX 281.50 ($3.77) on Thursday. The company has a quick ratio of 14.38, a current ratio of 14.31 and a debt-to-equity ratio of 8.37. The firm’s 50-day moving average price is GBX 318.96 and its two-hundred day moving average price is GBX 333.29. MaxCyte, Inc. has a 52-week low of GBX 180 ($2.41) and a 52-week high of GBX 430 ($5.75). The stock has a market capitalization of £295.83 million, a P/E ratio of -1,126.00 and a beta of 1.13.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.